Genmab was one of three bidders before inking $8B Merus acquisition

There were multiple bidders at the table for the fourth-largest biopharma acquisition of 2025, according to a regulatory filing, bucking the trend of single-suitor processes for many other deals this year. Last month, Genmab won ...